Literature DB >> 9144539

Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival.

M Hsiao1, V Tse, J Carmel, Y Tsai, P L Felgner, M Haas, G D Silverberg.   

Abstract

A cavitary glioblastoma model was created by injection of RT-2 cells, which express endogenous wild type p53, into the peritoneal cavity of nude mice. This model developed multiple layers of tumor cells invading the peritoneal surface and was used to mimic the postoperative surgical cavity remaining after glioblastoma (GBM) excision in patients. Rhodamine labeled DMRIE/DOPE + DNA complexes were found to penetrate at least 20 tumor cell layers. Injection of p53 gene/liposome complexes into the intraperitoneal cavity after the tumor was established resulted in massive tumor necrosis. Prominent staining of human p53 protein using the DO-1 antibody was found in tumor cells near the necrotic lesions. Tumor explants expressed human p53 protein and showed a 54% growth reduction in an in vitro growth assay. Further, DMRIE/DOPE mediated p53 gene transfection significantly increased the mean survival time of tumor bearing mice compared to vector control. These results demonstrate the efficiency of using exogenous wild type p53 to suppress glioblastoma cell with endogenous wild type p53 in vivo through liposome mediated transfection method.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144539     DOI: 10.1006/bbrc.1997.6459

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 3.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

4.  Antiangiogenic Gene Therapy in Cancer.

Authors:  L Zhang; Q R Chen; A J Mixson
Journal:  Curr Genomics       Date:  2000       Impact factor: 2.236

5.  Establishment of red fluorescent protein-tagged HeLa tumor metastasis models: determination of DsRed2 insertion effects and comparison of metastatic patterns after subcutaneous, intraperitoneal, or intravenous injection.

Authors:  Jau-Yeong Lu; Hui-Chun Chen; Ricky Yuan-Yuan Chu; Tsu-Chun Emma Lin; Ping-I Hsu; Ming-Shyan Huang; Ching-Jiunn Tseng; Michael Hsiao
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway.

Authors:  Hoon Ryu; Junghee Lee; Beatrix A Olofsson; Aziza Mwidau; Alpaslan Dedeoglu; Maria Escudero; Erik Flemington; Jane Azizkhan-Clifford; Robert J Ferrante; Rajiv R Ratan; Alpaslan Deodoglu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

7.  Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes.

Authors:  Y Yamaguchi; E Miyahara; A Ohshita; Y Kawabuchi; K Ohta; K Shimizu; K Minami; J Hihara; A Sawamura; T Toge
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.